VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more
VistaGen Therapeutics Inc (VTGN) - Net Assets
Latest net assets as of December 2025: $50.92 Million USD
Based on the latest financial reports, VistaGen Therapeutics Inc (VTGN) has net assets worth $50.92 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($65.06 Million) and total liabilities ($14.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $50.92 Million |
| % of Total Assets | 78.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -23.47% |
| 10-Year Change | N/A |
| Growth Volatility | 440.91 |
VistaGen Therapeutics Inc - Net Assets Trend (2008–2025)
This chart illustrates how VistaGen Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VistaGen Therapeutics Inc (2008–2025)
The table below shows the annual net assets of VistaGen Therapeutics Inc from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $70.39 Million | -38.41% |
| 2024-03-31 | $114.29 Million | +846.08% |
| 2023-03-31 | $12.08 Million | -81.33% |
| 2022-03-31 | $64.72 Million | -29.64% |
| 2021-03-31 | $91.98 Million | +1705.38% |
| 2020-03-31 | $-5.73 Million | -180.98% |
| 2019-03-31 | $7.08 Million | +2.29% |
| 2018-03-31 | $6.92 Million | +1023.19% |
| 2017-03-31 | $615.80K | +120.68% |
| 2016-03-31 | $-2.98 Million | +85.51% |
| 2015-03-31 | $-20.54 Million | -60.49% |
| 2014-03-31 | $-12.80 Million | -1.94% |
| 2013-03-31 | $-12.56 Million | -120.07% |
| 2012-03-31 | $-5.71 Million | -570460.00% |
| 2011-03-31 | $-1.00K | -706.45% |
| 2010-03-31 | $-124.00 | -100.61% |
| 2009-03-31 | $20.37K | +14151.03% |
| 2008-03-31 | $-145.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to VistaGen Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40762175500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $29.00K | 0.04% |
| Other Comprehensive Income | $5.00K | 0.01% |
| Other Components | $477.99 Million | 679.06% |
| Total Equity | $70.39 Million | 100.00% |
VistaGen Therapeutics Inc Competitors by Market Cap
The table below lists competitors of VistaGen Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
$21.83 Million |
|
Strategic Resources Inc
PINK:SCCFF
|
$21.84 Million |
|
CALGRO M3 HLDGS RC-00001
F:5C2
|
$21.84 Million |
|
Singsongholdin
KO:006880
|
$21.85 Million |
|
Star Comgistic Capital Co Ltd
TW:4930
|
$21.82 Million |
|
Pakka Limited
NSE:PAKKA
|
$21.81 Million |
|
Min Aik Precision Industrial Co Ltd
TW:4545
|
$21.81 Million |
|
Southern Steel Bhd
KLSE:5665
|
$21.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VistaGen Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 114,286,000 to 70,390,000, a change of -43,896,000 (-38.4%).
- Net loss of 51,418,000 reduced equity.
- New share issuances of 3,009,000 increased equity.
- Other comprehensive income increased equity by 5,000.
- Other factors increased equity by 4,508,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-51.42 Million | -73.05% |
| Share Issuances | $3.01 Million | +4.27% |
| Other Comprehensive Income | $5.00K | +0.01% |
| Other Changes | $4.51 Million | +6.4% |
| Total Change | $- | -38.41% |
Book Value vs Market Value Analysis
This analysis compares VistaGen Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 115.66x to 0.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-03-31 | $0.01 | $0.65 | x |
| 2009-03-31 | $1.17 | $0.65 | x |
| 2010-03-31 | $-0.01 | $0.65 | x |
| 2011-03-31 | $-0.05 | $0.65 | x |
| 2012-03-31 | $-232.30 | $0.65 | x |
| 2013-03-31 | $-416.04 | $0.65 | x |
| 2014-03-31 | $-349.34 | $0.65 | x |
| 2015-03-31 | $-467.31 | $0.65 | x |
| 2016-03-31 | $-50.52 | $0.65 | x |
| 2017-03-31 | $2.45 | $0.65 | x |
| 2018-03-31 | $14.94 | $0.65 | x |
| 2019-03-31 | $7.43 | $0.65 | x |
| 2020-03-31 | $-3.92 | $0.65 | x |
| 2021-03-31 | $32.04 | $0.65 | x |
| 2022-03-31 | $9.81 | $0.65 | x |
| 2023-03-31 | $1.74 | $0.65 | x |
| 2024-03-31 | $5.90 | $0.65 | x |
| 2025-03-31 | $2.29 | $0.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VistaGen Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10579.84%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.20x
- Recent ROE (-73.05%) is above the historical average (-443.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -5004.21% | 0.00% | 0.00x | 1.00x | $-4.76K |
| 2009 | -80.57% | 0.00% | 0.00x | 1.13x | $-18.45K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.99K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.88K |
| 2012 | 0.00% | -909.66% | 3.93x | 0.00x | $-11.64 Million |
| 2013 | 0.00% | -6430.49% | 0.23x | 0.00x | $-11.63 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.69 Million |
| 2015 | 0.00% | 0.00% | -0.50x | 0.00x | $-11.83 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.92 Million |
| 2017 | -1665.39% | -820.44% | 0.34x | 6.03x | $-10.32 Million |
| 2018 | -207.41% | 0.00% | 0.00x | 1.63x | $-15.04 Million |
| 2019 | -347.55% | 0.00% | 0.00x | 1.98x | $-25.30 Million |
| 2020 | 0.00% | -6219.76% | 0.06x | 0.00x | $-20.20 Million |
| 2021 | -19.50% | -1646.09% | 0.01x | 1.18x | $-27.13 Million |
| 2022 | -73.80% | -4307.19% | 0.01x | 1.15x | $-54.23 Million |
| 2023 | -490.46% | 0.00% | -0.01x | 1.75x | $-60.46 Million |
| 2024 | -25.69% | -2759.59% | 0.01x | 1.08x | $-40.79 Million |
| 2025 | -73.05% | -10579.84% | 0.01x | 1.20x | $-58.46 Million |
Industry Comparison
This section compares VistaGen Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VistaGen Therapeutics Inc (VTGN) | $50.92 Million | -5004.21% | 0.28x | $21.83 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |